Biophytis SA · EURONEXT:ALBPS

Biophytis SA — JPM 2018

31 slides from Biophytis SA's conference presentation, January 2018

  1. Slide 1: New Therapeutics for Diseases of Aging

    Slide 1: New Therapeutics for Diseases of Aging

    biophytis NEW THERAPEUTICS FOR DISEASES OF AGING THE BIOTECH SPECIALISED IN DISEASES OF AGING

  2. Slide 2: Disclaimer

    Slide 2: Disclaimer

    DISCLAIMER Important Information and Forward Looking Statements • BIOPHYTIS IS A PUBLIC COMPANY LISTED ON THE ALTERNEXT MARKET OF EURONEXT PARIS STOCK EXCHANGE SINCE JULY 13, 2015. • THIS DOCUMENT DOES NOT CONSTITUTE OR FORM PART OF ANY OFFER FOR SALE OR SUBSCRIPTION OF OR SOLICITATION OF ANY OFFER

  3. Slide 3: Corporate Overview

    Slide 3: Corporate Overview

    CORPORATE OVERVIEW BIOPHYTIS is a public company listed on Euronext Growth (Paris, France) • Share price (January 2nd 2018): €4,72 • Shares outstanding: 13,463,413 • Market capitalization: €63 M • €16 M raised in 2015; €28 M raised in 2017 BIOPHYTIS is advancing two drug candidates into Phase II SAR

  4. Slide 4: A Seasoned Management Team

    Slide 4: A Seasoned Management Team

    THE TEAM Stanislas VEILLET René LAFONT Founder & CEO Co-founder & CSO • PhD in genetics, AgroParisTech • Professor emeritus at alumnus Sorbonne Université • 15+ years in R&D management • Former Dean of the life (Monsanto, Pharmacia, sciences department Danone) • 170+ peer-reviewed • Created Biophyti

  5. Slide 5: Drug Discovery & Development Strategy

    Slide 5: Drug Discovery & Development Strategy

    DRUG DISCOVERY & DEVELOPMENT STRATEGY First generation Second generation • Active principles derived • New chemical entities from plant substances • Optimized • Preclinical proof of pharmacology concept • IP on composition of • Well tolerated in matter humans • IP on use and process Biophytis has id

  6. Slide 6: Pipeline

    Slide 6: Pipeline

    blophytis PIPELINE CANDIDATES INDICATION PRECLINICAL | pHasE: | PHASE Il | PHASE | SARCONEOS SARCOPENIA ee DYSTROPHIES ACTIVATORS > —=)> MACUNEOS

  7. Slide 7: Scientific Board

    Slide 7: Scientific Board

    SCIENTIFIC BOARD Pr. Jean MARIANI Pr. René LAFONT Pr. José SAHEL Director of Institut de la Professor emeritus Director of longévité Charles Foix Former Dean of the life Institut de la sciences department Vision WORLD CLASS SCIENTIFIC LEADERS CONTRIBUTE TO THE DEVELOPMENT OF OUR DRUG CANDIDATES Dr.

  8. Slide 8: MAS Activators and Muscular Diseases

    Slide 8: MAS Activators and Muscular Diseases

    MAS ACTIVATORS AND MUSCULAR DISEASES GERIATRIC CHRONIC DISEASE: SARCOPENIA PAEDIATRIC ORPHAN DISEASE DUCHENNE’S MUSCULAR DYSTROPHY (DMD)

  9. Slide 9: Renin Angiotensin System (RAS) and Muscle Anabolism

    Slide 9: Renin Angiotensin System (RAS) and Muscle Anabolism

    RENIN ANGIOTENSIN SYSTEM (RAS) AND MUSCLE ANABOLISM Targeting RAS stimulates anabolism in muscle and has potential for the treatment of chronic or genetic muscle disorders 9

  10. Slide 10: MAS Activation

    Slide 10: MAS Activation

    MAS ACTIVATION SARCONEOS is a potent MAS activator that stimulates protein synthesis, energy production and regeneration in muscle 10

  11. Slide 11: Sarcopenia

    Slide 11: Sarcopenia

    SARCOPENIA • Definition: Low muscle strength and low muscle mass (FNIH criteria) ICD-10 Code: M62.84 • Prevalence: 50M patients Estimated at 5 – 10% in >65 years old • Standard of Care: 30 minutes physical exercise / day No currently approved medication Drug candidates in development Examples Myosta

  12. Slide 12: Sarconeos: Proof of Concept in Animals

    Slide 12: Sarconeos: Proof of Concept in Animals

    SARCONEOS: PROOF OF CONCEPT IN ANIMALS SARCONEOS compensates the effect of ageing SARCONEOS stimulates anabolism in on muscle functionality and mobility muscle Increase in protein quantity in muscle Increase in running speed in old mice Inhibition of myostatin expression in muscle SARCONEOS stimulat

  13. Slide 13: Sarconeos: Proof of Activity in Nutritional Trial

    Slide 13: Sarconeos: Proof of Activity in Nutritional Trial

    SARCONEOS: PROOF OF ACTIVITY IN NUTRITIONAL TRIAL QUINOLIA – Safety, PK and pharmacodynamic parameters in obese healthy volunteers • 58 subjects, double-blind, placebo-controlled, nutrition study (dieting) • Oral administration (40 mg/day) for 12 weeks (6 weeks hypocaloric dieting) • No serious adve

  14. Slide 14: Sarconeos: Proof of Safety in Phase I Study

    Slide 14: Sarconeos: Proof of Safety in Phase I Study

    SARCONEOS: PROOF OF SAFETY IN PHASE I STUDY SARA-PK – Phase 1 – Safety, PK and PD in elderly healthy volunteers • 54 elderly subjects (>65 years), combined SAD (24 elderly and young subjects) + MAD step (30 elderly subjects) • MAD after oral administration of 350 mg/day, 700 mg/day or 900 mg/day for

  15. Slide 15: SARA: Phase 2b International Clinical Program

    Slide 15: SARA: Phase 2b International Clinical Program

    SARA: PHASE 2b INTERNATIONAL CLINICAL PROGRAM SARA-OBS - Observational study • Multicentric observational study: eight clinical centers in Europe and the US • Recruitment of sarcopenic patients in Europe and US on going • 300 sarcopenic patients: Foundation of NIH inclusion criteria for sarcopenia •

  16. Slide 16: Duchenne's Muscular Dystrophy (DMD)

    Slide 16: Duchenne's Muscular Dystrophy (DMD)

    DUCHENNE’S MUSCULAR DYSTROPHY (DMD) • Definition: Genetic disease characterized by progressive muscle degeneration • Prevalence: Around 5 per 100,000 males • Incidence: 1 in 3,500 male births • Standard of Care: Corticosteroids Drug candidates in development Examples Genetic and cell therapy Exon Sk

  17. Slide 17: Sarconeos: Proof of Concept in Animals

    Slide 17: Sarconeos: Proof of Concept in Animals

    SARCONEOS: PROOF OF CONCEPT IN ANIMALS SARCONEOS improves exercise tolerance in mdx SARCONEOS reduces fibrosis and mice lesional profile in mdx mice muscles Lesional profile 1200 Control 1000 mdx mdx Sarconeos Control SARCONEOS strongly improves muscle function and decreases muscle fibrosis in the s

  18. Slide 18: Sarconeos: Clinical Development Plan in DMD

    Slide 18: Sarconeos: Clinical Development Plan in DMD

    SARCONEOS: CLINICAL DEVELOPMENT PLAN IN DUCHENNE’S MUSCULAR DYSTROPHY Paediatric PK Study • Phase 1 trial in ambulant Duchenne boys • SAD, MAD Interventional Phase 2B trial • Multicentric international clinical trial • Ambulant Duchenne boys 18 19

  19. Slide 19: PPAR Activators and Retinal Diseases

    Slide 19: PPAR Activators and Retinal Diseases

    - PPAR ACTIVATORS AND \__ RETINAL DISEASES g CHRONIC DISEASE: | DRY AGE-RELATED MACULAR DEGENERATION (AMD) | PAEDIATRIC ORPHAN DISEASE: STARGARDT’S DISEASE

  20. Slide 20: Photo-Oxidative Stress and Macular Degeneration

    Slide 20: Photo-Oxidative Stress and Macular Degeneration

    PHOTO-OXIDATIVE STRESS AND MACULAR DEGENERATION A2E and oxydative stress • A2E is a derivative of visual pigment • A2E accumulates in Retinal Pigment Epithelium (RPE) cells • A2E is a very reactive molecule that causes oxidative stress with exposure to light, leading to macular degeneration Photo-ox

  21. Slide 21: PPAR Activation

    Slide 21: PPAR Activation

    PPAR ACTIVATION MACUNEOS activates PPAR nuclear receptors and protects the retina from oxidative stress associated with accumulation of A2E. •  Cell death •  Free radicals production •  VEGF production •  Inflammation MACUNEOS is an activator of PPARs and limits the degeneration of the retina ca

  22. Slide 22: Dry Age-Related Macular Degeneration (AMD)

    Slide 22: Dry Age-Related Macular Degeneration (AMD)

    DRY AGE-RELATED MACULAR DEGENERATION (AMD) • Definition: All forms of AMD which are not neovascular and exsudative • Prevalence: Estimated at 20M globally • Standard of Care: Zinc + Vitamines C/E (nutraceuticals) Drug candidates in development Examples Anti-complement factor antibodies Lampaluzimab

  23. Slide 23: Macuneos: Proof of Concept in Animals

    Slide 23: Macuneos: Proof of Concept in Animals

    MACUNEOS: PROOF OF CONCEPT IN ANIMALS MACUNEOS preserves the retina’s functionality and MACUNEOS preserves the number of layers of limits the A2E accumulation after chronic oral photoreceptors after a light stress (Blue light administration (ABCA4-/- RDH8-/- mice model) rat model) MACUNEOS protects

  24. Slide 24: Macuneos: Safety and Proof of Concept in Humans

    Slide 24: Macuneos: Safety and Proof of Concept in Humans

    MACUNEOS: SAFETY AND PROOF OF CONCEPT IN HUMANS BIXILIA –Safety and PK in healthy volunteers • 47 healthy volunteers • Oral administration (35 mg/day) for 12 weeks • Double-blind, placebo-controlled, nutrition study • No serious adverse event • Achieved target for bioavailability MACA-PK – Phase 1/2

  25. Slide 25: MACA: Phase 2b International Clinical Program

    Slide 25: MACA: Phase 2b International Clinical Program

    MACA: PHASE 2B INTERNATIONAL CLINICAL PROGRAM MACA-OBS – Observational study in patients with dry AMD • Multicentric observational study: clinical centers in Europe and the US • 100 patients suffering of intermediate dry AMD • Duration: 6 months • Endpoints: atrophic lesion size, ERG, visual acuity

  26. Slide 26: Stargardt's Disease

    Slide 26: Stargardt's Disease

    STARGARDT’S DISEASE • Definition: Genetically determined Juvenile Macular Degeneration • Prevalence: Estimated at 1 in 10,000 • Standard of Care: Eyeglasses / Sunglasses Currently no approved therapeutic Drug Candidates in Development MACUNEOS preserves the retina structure after intra-vitreal injec

  27. Slide 27: Value Creation News Flow

    Slide 27: Value Creation News Flow

    VALUE CREATION NEWS FLOW SARCONEOS in SARCOPENIA • H1 18: SARA-OBS: Interim results of the observational phase, in Europe and US • H1 18: SARA-INT: Initiation of the interventional Phase 2b SARA • H2 18: SARA-INT: Interim results of the interventional Phase 2b SARA (DSMB) • H2 18: SARA-INT: Results

  28. Slide 28: A Board of Directors with Complementary Profiles

    Slide 28: A Board of Directors with Complementary Profiles

    THE BOARD OF DIRECTORS Jean M. Franchi Stanislas VEILLET Marie-Claire JANAILHAC- Independant Board Chairman of the FRITCH Member Board Independant Board • BA in Finance in • PhD in genetics, Member Hofstra alumnus AgroParisTech • HEC alumnus • CFO for Merrimack alumnus • President of the Board, Phar

  29. Slide 29: Capital Structure

    Slide 29: Capital Structure

    CAPITAL STRUCTURE Stock profile • Market: Euronext Growth of Euronext Paris • Ticker: ALBPS • Shares outstanding: 13,463,413 • Share price (January 2d 2018): €4,72/share • Market Capitalization: €63 M 29 29

  30. Slide 30: Highlights

    Slide 30: Highlights

    HIGHLIGHTS SARCONEOS to treat sarcopenia and Duchenne’s Disease 1 • SARA-INT Phase 2b trial about to start H1 2018, reporting H2 2018 • DMD clinical program planned to start H2 2018 MACUNEOS to treat dry AMD and Stargardt’s Disease 2 • MACA-PK Phase 1 study about to start H1 2018, reporting H2 2018

  31. Slide 31: Thank you

    Slide 31: Thank you

    Thank you Investors contact: investors@biophytis.com 31

Source: Internet Archive copy of biophytis.com

More decks from Biophytis SA

All 35 Biophytis SA decks